Quick Summary:
In an increasingly dynamic healthcare environment, the Global Acute Coronary Syndrome Market is projected to expand dramatically, with a revised forecast predicting the industry to reach $17.6 Billion by 2030. This impressive growth trajectory, from an estimated valuation of $7.9 Billion in 2022, underscores the critical potential of investment opportunities within this economically significant market.
For senior executives seeking to stay abreast of evolving trends, this comprehensive report offers an invaluable roadmap of the Acute Coronary Syndrome market. Notably, it shows the U.S. market is valued at $2.1 billion, while China's fateful expansion is expected to surge at a 16.6% CAGR, reaching $4.5 billion by 2030. Including critical insights into growing geographical markets, such as Japan and Canada, and solid performers like Germany, the report equips visionaries with the intelligence needed to navigate the future of the healthcare landscape.
Global Acute Coronary Syndrome Market to Reach $17.6 Billion by 2030
The global market for Acute Coronary Syndrome estimated at US$7.9 Billion in the year 2022, is projected to reach a revised size of US$17.6 Billion by 2030, growing at a CAGR of 10.6% over the analysis period 2022-2030.
The U.S. Market is Estimated at $2.1 Billion, While China is Forecast to Grow at 16.6% CAGR
The Acute Coronary Syndrome market in the U.S. is estimated at US$2.1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$4.5 Billion by the year 2030 trailing a CAGR of 16.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.7% and 10.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.6% CAGR.Select Competitors (Total 62 Featured) -
- Amgen, Inc.
- Astellas Pharma, Inc.
- AstraZeneca PLC
- Biological E. Ltd.
- Daiichi Sankyo Co., Ltd.
- Dr. Reddy's Laboratories Ltd.
- Eisai Co., Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Johnson & Johnson
- Momenta Pharmaceuticals, Inc.
- Pfizer, Inc.
- Recordati SpA
- The Medicines Company
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Acute Coronary Syndrome?
What is the growth rate of the Global Market for Acute Coronary Syndrome?
What is the forecasted size of the Global Market for Acute Coronary Syndrome?
Who are the key companies in the Global Market for Acute Coronary Syndrome?
| Report Attribute | Details |
|---|---|
| No. of Pages | 182 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 7.9 Billion |
| Forecasted Market Value ( USD | $ 17.6 Billion |
| Compound Annual Growth Rate | 10.5% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- Amgen, Inc.
- Astellas Pharma, Inc.
- AstraZeneca PLC
- Biological E. Ltd.
- Daiichi Sankyo Co., Ltd.
- Dr. Reddy's Laboratories Ltd.
- Eisai Co., Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Johnson & Johnson
- Momenta Pharmaceuticals, Inc.
- Pfizer, Inc.
- Recordati SpA
- The Medicines Company
